Correction to: Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial.
Publication
, Journal Article
Eckhardt, CM; Cummings, MJ; Rajagopalan, KN; Borden, S; Bitan, ZC; Wolf, A; Kantor, A; Briese, T; Meyer, BJ; Jacobson, SD; Scotto, D; Shaz, B ...
Published in: Trials
June 16, 2020
An amendment to this paper has been published and can be accessed via the original article.
Duke Scholars
Published In
Trials
DOI
EISSN
1745-6215
Publication Date
June 16, 2020
Volume
21
Issue
1
Start / End Page
536
Location
England
Related Subject Headings
- General & Internal Medicine
- Cardiovascular System & Hematology
- 4203 Health services and systems
- 4202 Epidemiology
- 3202 Clinical sciences
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Eckhardt, C. M., Cummings, M. J., Rajagopalan, K. N., Borden, S., Bitan, Z. C., Wolf, A., … O’Donnell, M. R. (2020). Correction to: Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial. Trials, 21(1), 536. https://doi.org/10.1186/s13063-020-04504-x
Eckhardt, Christina M., Matthew J. Cummings, Kartik N. Rajagopalan, Sarah Borden, Zachary C. Bitan, Allison Wolf, Alex Kantor, et al. “Correction to: Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial.” Trials 21, no. 1 (June 16, 2020): 536. https://doi.org/10.1186/s13063-020-04504-x.
Eckhardt CM, Cummings MJ, Rajagopalan KN, Borden S, Bitan ZC, Wolf A, et al. Correction to: Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial. Trials. 2020 Jun 16;21(1):536.
Eckhardt, Christina M., et al. “Correction to: Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial.” Trials, vol. 21, no. 1, June 2020, p. 536. Pubmed, doi:10.1186/s13063-020-04504-x.
Eckhardt CM, Cummings MJ, Rajagopalan KN, Borden S, Bitan ZC, Wolf A, Kantor A, Briese T, Meyer BJ, Jacobson SD, Scotto D, Mishra N, Philip NM, Stotler BA, Schwartz J, Shaz B, Spitalnik SL, Eisenberger A, Hod EA, Justman J, Cheung K, Lipkin WI, O’Donnell MR. Correction to: Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial. Trials. 2020 Jun 16;21(1):536.
Published In
Trials
DOI
EISSN
1745-6215
Publication Date
June 16, 2020
Volume
21
Issue
1
Start / End Page
536
Location
England
Related Subject Headings
- General & Internal Medicine
- Cardiovascular System & Hematology
- 4203 Health services and systems
- 4202 Epidemiology
- 3202 Clinical sciences
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology